DALLAS–(BUSINESS WIRE)–Lantern Pharma Inc. (NASDAQ: LTRN), an AI‑driven precision oncology company transforming the cost, pace, and timeline of oncology drug discovery and development, today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. Patent Application No. 18/500,032, titled “Method for Treating Blood Cancers,” with claims directed to the use of the company’s drug candidate LP‑284 to treat patients with mantle cell lymphoma (